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Protein kinase CInduction of the suppressor of cytokine signalling 3 (SOCS-3) gene is vital to the normal control of inﬂamma-
tory signalling. In order to understand these processes we investigated the role of the proto-oncogene com-
ponent of the AP-1 transcription factor complex, c-Jun, in the regulation of SOCS-3 gene induction. We found
that cyclic AMP stimulation of HUVECs promoted phosphorylation and activation of JNK MAP kinase and its
substrate c-Jun. The JNK responsive element of the human SOCS-3 promoter mapped to a putative AP-1 site
within 1000 bp of the transcription start site. The PKC inhibitors, GF-109203X, Gö-6983 and Ro-317549, were
all found to inhibit AP-1 transcriptional activity, transcriptional activation of this minimal SOCS-3 promoter
and SOCS-3 gene induction in HUVECs. Interestingly, Ro-317549 treatment was also found to promote PKC-
dependent activation of ERK and JNK MAP kinases and promote JNK-dependent hyper-phosphorylation of
c-Jun, whereas GF-109203X and Gö-6983 had little effect. Despite this, all three PKC inhibitors were found
to be effective inhibitors of c-Jun DNA-binding activity. The JNK-dependent hyper-phosphorylation of c-Jun
in response to Ro-317549 treatment of HUVECs does therefore not interfere with its ability to inhibit c-Jun
activity and acts as an effective inhibitor of c-Jun-dependent SOCS-3 gene induction.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
The suppressor of cytokine signalling (SOCS) protein family con-
sists of eight closely related members, cytokine inducible Src homol-
ogy 2 protein (CIS) and SOCS-1 to 7 [1]. The basic structure of SOCS
proteins consists of a central SH-2 and a C-terminal SOCS box domain
[1]. SOCS-3, in particular, has been studied extensively and is known
to play a vital role in the regulation of inﬂammatory processes [1,2].
For example, levels of SOCS-3 protein are increased at sights of in-
ﬂammation [3] and conditional deletion of the SOCS-3 gene inonophosphate; C/EBP, CCAAT/
endothelial cell; SOCS-3, sup-
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, extracellular signal regulated
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rights reserved.hematopoietic and endothelial cells causes mice to die from severe
inﬂammatory lesions [4]. Pro-inﬂammatory cytokines, such as inter-
leukin 6 (IL-6), activate the Janus kinase (JAK)/signal transducer
and activator of transcription (STAT) pathway, leading to the induc-
tion of the SOCS-3 gene [2]. SOCS-3 protein inhibits the JAK-STAT
pathway, forming part of a negative feedback loop [1]. SOCS-3 can
down-regulate the JAK-STAT signalling through several mechanisms,
including targeting SH-2 bound proteins for ubiquitination and pro-
teosomal degradation, through the recruitment of an E2 ubiquitin
transferase [5], competitively inhibiting JAK proteins binding to the
receptor and inhibiting STAT activation through its kinase inhibitory
region (KIR) [1].
It has been demonstrated that recombinant cell-penetrating forms
of SOCS-3 protein can serve as an effective therapy against pathogen-
derived acute inﬂammation [6]. Clearly, therefore, small molecule
regulators of SOCS-3 gene activity could also have a similar effect in
combating acute and chronic inﬂammation [7]. In this respect we
have aimed investigations into unravelling the molecular control of
SOCS-3 gene activity and have found that induction of SOCS-3 by cy-
clic AMP has an anti-inﬂammatory effect in vascular endothelial
cells [8,9]. Here, elevations in intracellular cyclic AMP lead to SOCS-3
gene induction through the mobilisation of C/EBP transcription
1691J. Wiejak et al. / Cellular Signalling 24 (2012) 1690–1699factors β and δ through the concomitant activation of exchange pro-
tein activated by cAMP 1 (EPAC1) and the ERK MAP kinase pathway
[10–12]. Further work in COS1 cells highlighted a potential role for
protein kinase C isoforms α and δ, acting downstream of EPAC1 in
the pathway leading to SOCS-3 induction [13]. In the current work
we aim to further delineate the signalling mechanisms underlying cy-
clic AMP-regulated SOCS-3 induction in VECs in order to deﬁne future
targets for therapeutic intervention. To this end we have investigated
the mechanisms of action of the bisindolemaleimide PKC inhibitors,
RO-318220 [14] Gö-6983 [15] and GF-109203X [16], which we previ-
ously determined to be effective inhibitors of cyclic AMP-induced
SOCS-3 induction in COS1 cells [10]. Our results demonstrate a num-
ber of “off-target” effects of RO-318220 that, nevertheless, allowed us
to identify the transcription factor c-Jun as a key regulator of cyclic
AMP-induced SOCS-3 gene induction in VECs.
2. Materials and methods
2.1. Materials
Primary antibodies to anti-total ERK, anti-phospho-ERK (Thr202/
Tyr204), anti-total c-Jun, anti-phospho-c-Jun (Ser63), anti-total JNK,
anti-phospho-JNK, pan-PKC and anti-β‐tubulin were purchased
from New England Biolabs. Anti-SOCS-3 antibody was from Santa
Cruz Biotechnology. Secondary antibodies anti-rabbit, anti-goat and
anti-mouse IgG conjugated with HRP were purchased from GE
Healthcare. Forskolin, rolipram, 12-myristate 13-acetate (PMA),
MG132, U0126, SB 202190, JNK inhibitor III, GF-109203X, GÖ-6983
and Ro-317549 were purchased from Merck/Calbiochem. The AP-1
reporter construct was provided by Professor Walter Kolch, Universi-
ty College, Dublin.
2.2. Cell culture and transfections
COS-1 cells were grown in 75 cm2 tissue culture ﬂasks in Dulbecco's
modiﬁed Eagle's medium (Sigma-Aldrich) supplemented with 10%
(v/v) foetal bovine serum (Sigma-Aldrich UK), 2 mM glutamine and
2% (v/v) penicillin/streptomycin (Sigma-Aldrich UK) at 37 °C in a hu-
midiﬁed 5% (v/v) CO2 atmosphere. Human umbilical vein endothelial
cells (HUVECs) were grown in human endothelial cell growth medium
2 (PromoCell Heidelberg, Germany) at 37 °C in humidiﬁed 5% (v/v)
CO2. Cultures of 80%–90% conﬂuent COS-1 cells grown on 12-well
culture clusters were transfected with 0.125 μg Renilla Luciferase re-
porter construct (pGL4.74) plus 1.125 μg of human SOCS3-Luc promot-
er constructs. Plasmids were diluted in a total volume of 12.5 μl Hanks
balanced salt solution (HBS; Sigma-Aldrich UK) before being added to
25 μl transfection agent 30% (v/v) DOTAP (Roche, UK) in HBS. Trans-
fected cells were then incubated overnight at 37 °C and experiments
carried out the next day.2.3. Generation of human SOCS-3 promoter constructs
A 1.7 kbp fragment of the human SOCS-3 promoter cloned into pGL3-
Basic (hSOCS3-1.7 kbp) was generously provided by Dr. Jason Mathews,
University of Toronto [17]. Consecutive promoter truncatesweregenerated
with the QuikChange II Site-Directed Mutagenesis Kit (Agilent) using
this promoter fragment as an initial template. The primers used were
hSOCS3-1.1 kbp (forward 5′-GCCGAGGCTGGGTAGCCCCTGCTCGCGGCC-3′
and reverse 5′‐GGCCGCGAGCAGGGGCTACCCAGCCTCGGC-3′), hSOCS3-
1.1-T1 (forward 5′-GCCGAGGCTGGGTAGTTTCTCTGCTGCG-3′ and reverse
5′-CGCAGCAGAGAAACTACCCAGCCTCGGC-3′), hSOCS3-1.1-T2 (forward
5′‐GCCGAGGCTGGGTAGGCCGGCCGCGCAGTTCC-3′ and reverse 5′-GGA-
ACTGCGCGGCCGGCCTACCCAGCCTCGGC-3′) and hSOCS3-1.1-T3 (forward
5′-GCCGAGGCTGGGTAGGCGGGGCGCGGCGGC-3′ and reverse 5′‐GCCG-
CCGCGCCCCGCCTACCCAGCCTCGGC-3′). The putative AP-1 site in pGL3-Basic-hSOCS3-1.1-T1 was disrupted (GTGACTAA to AAGCTTAA, generat-
ing T1-delta AP1) usingQuikChangemutagenesis and the primers, forward
5′-GCTGCGAGTAAAGCTTAAACATTACAAGAAGGCCGGCCGCGC-3′ and re-
verse 5′‐GCGCGGCCGGCCTTCTTGTAATGTTTAAGCTTTACTCGCAGC-3′.2.4. Dual Luciferase Reporter Assays
COS-1 cells transfected with human SOCS3-Luc promoter con-
structs were incubated for 16 h in the presence or absence of 10 μM
or 0.1 μM phorbol 12-myristate 13-acetate (PMA) (Merck, UK). In
some experiments cells were co-incubated with 10 μM SB600125,
10 μM JNK inhibitor III, 10 μM SB202190, 10 μM U0126, 5 μM RO-
317549, 25 μM Gö-6983, 25 μM GF-109203X. After incubation the
medium was removed and the cells washed with PBS. Cells were
then lysed with 250 μl of 1× passive lysis buffer (Promega, UK) and
placed on a rocking platform for 20 min at room temperature. Cell ly-
sates were collected and 20 μl samples were assayed in triplicate for
luciferase activity using the Promega Dual Luciferase Reporter Assay
System according to the manufacturers' protocols. Luciferase activi-
ties were measured using a BMG Labtech luminometer.2.5. RT-PCR
HUVECs were incubated with the indicated drugs, washed with PBS,
harvested by scraping into 350 μl RLT buffer (Qiagen) and then lysed
with 10 passes through a 21-gauge needle attached to a 1 ml plastic sy-
ringe. RNA was then extracted from cell extracts using the Qiagen
RNeasyMini kit according to themanufacturer's protocols. RNA samples
were then dilutedwith water to a ﬁnal concentration of 5 ng/μl RNA and
the RT-PCR reaction was carried out using the Qiagen One-Step RT-PCR
Kit, using 0.4 mM dNTPs and 0.6 μM of each primer, according to pub-
lished protocols. Theprimers usedwere, hSOCS3-Forward, 5′-CACATGG-
CACAAGCACAAGA-3′, hSOCS3-Reverse, 5′-AAGTGTCCCCTGTTTGGAGG-
3′, actin-Forward, 5′-CTGGCACCCAGCACAATG-3′ and actin-Reverse,
5′-GCCGATCCACACGGAGTACT-3′. The RT-PCR programme consisted of
30 min at 50 °C, 15 min at 95 °C and then 30 cycles of 30 s at 94 °C,
30 s at 50 °C and72 °C followed by10 min at 72 °C. The RT-PCRproducts
were resolved on 1.5% (w/v) agarose gels for 1 h at 80 V.2.6. Intracellular Ca2+ measurements
HUVECs were grown overnight and then loaded with 1 mM FURA-
2. Cells were then stimulated with the indicated treatments and
changes in intracellular Ca2+ concentration were determined as pre-
viously described [18].2.7. Immunoblotting
Cells lysates were prepared in sample buffer (50 mM Tris–HCl,
pH6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-Mercaptoethanol,
12.5 mM EDTA, 0.02% (w/v) bromophenol blue, 100 mM DTT). Protein
samples were then separated by SDS-PAGE on 10% (w/v) gels, trans-
ferred to nitrocellulose, blocked for 1 h at room temperature in 5% (w/v)
BSA, immunoblotted with antibodies speciﬁc for JNK, phospho-JNK,
ERK, phospho-ERK, c-Jun, phospho-c-Jun or PKC and then developed
using ECL chemiluminescence (GE Healthcare).2.8. c-Jun activation assay
A TransAM™ AP-1/c-Jun activation kit was purchased from Active
Motif. Following stimulation nuclear extracts were prepared from
HUVEC cells using an Active Motif nuclear extract kit, according to
1692 J. Wiejak et al. / Cellular Signalling 24 (2012) 1690–1699the manufacturers' instructions. Equal amounts of nuclear extract
were then added to ELISA plates coated with oligonucleotides corre-
sponding to the AP-1 consensus sequence and developed with an
anti-c-Jun antibody. The extent of c-Jun binding to AP-1 oligonucleo-
tides was determined colourimetrically using a spectrophotometer
set at 495 nm.
2.9. Statistics
Data was analysed using one-way analysis of variance (ANOVA)
with a Tukey–Kramer post test.
3. Results and discussion
3.1. Effects of Ro-317549 on SOCS-3 gene induction
We had previously demonstrated that bisindoylmalemide pro-
tein kinase C (PKC) inhibitors effectively inhibited SOCS-3 geneAntibody
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Fig. 1. Protein kinase C inhibitors block human SOCS-3 gene induction in HUVECs. A). H
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Total RNA was then extracted from cells and subjected to one-step RT-PCR, with spec
pliﬁed DNA fragments were visualised by agarose gel electrophoresis.induction in response to cyclic AMP-elevation in COS1 cells [10].
We therefore sought to assess the effect of this class of inhibitor
on SOCS-3 protein induction by cyclic AMP in HUVECs, which rep-
resents a valid model of the suppressive effects of cyclic AMP on
endothelial dysfunction [9]. HUVECs were therefore stimulated
with various concentrations of the structurally related PKC inhibi-
tors Ro-31-7459, GÖ-6983 or GF-109203X and either a combina-
tion of the adenylate cyclase activator, forskolin, and the type IV,
cyclic AMP-speciﬁc phosphodiesterase inhibitor, rolipram (F/R)
or the phorbol ester activator of novel and conventional PKC iso-
forms, PMA (Fig. 1). Experiments were carried out in the presence
of the proteasome inhibitor, MG132, to prevent SOCS-3 degrada-
tion following synthesis so that effects solely on protein induction
could be monitored. Immunoblotting cell extracts with anti-SOCS-
3 antibodies demonstrated that GÖ-6983 and GF-109203X inhib-
ited SOCS-3 induction in response to both F/R and PMA, with
maximal inhibition occurring at around 25 μM for both inhibitors
(Fig. 1A and B). In contrast, however, Ro-31-7459 effectively- + -
- - +
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iﬁc primers towards SOCS-3 or actin, as described in Materials and methods. Am-
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inhibition occurring at 5 μM (Fig. 1A and B), indicating that per-
haps this inhibitor was acting through mechanisms distinct from
GÖ-6983 and GF-109203X.
To determine whether any of the PKC inhibitors was acting at
the level of SOCS-3 gene induction, RT-PCR reactions were car-
ried out on F/R- and PMA-stimulated cell extracts using speciﬁc
primers to SOCS-3 mRNA. As can be seen in Fig. 1C, all three
PKC inhibitors blocked SOCS-3 mRNA production in response to
PMA and F/R treatment, and that Ro-31-7459 was equally effec-
tive at 5 μM. These experiments show that Ro-31-7459 is an
effective inhibitor of SOCS-3 gene expression in HUVECs in re-
sponse to PKC activation or elevations in intracellular cyclic
AMP as induced following F/R treatment. The fact that PKC inhib-
itors effectively block cyclic AMP-stimulated SOCS-3 gene induc-
tion implies that PKC conventional and novel PKC isoforms may
lie downstream of cyclic AMP production in the pathway leading
to gene activation. While there is some evidence that cyclic AMP
can regulate PKC activity in certain cell contexts, perhaps
through the activation of Rap1-dependent phospholipase Cε
[10], we have so far been unable to detect activation of PKC iso-
forms or mobilisation of intracellular calcium, following cyclic
AMP stimulation of HUVECs, as detected by FURA2-labelling of
cells and immunoblotting for phosphorylated PKC-substrates
(Fig. 2). The fact that the PKC inhibitors are acting at the level
of the SOCS-3 gene (Fig. 1C) suggests that they may be modifying
the basal activity of one or more transcription factors linked to
SOCS-3 induction.3.2. Effects of PKC inhibitors on c-Jun phosphorylation
Given that the structurally related PKC inhibitor, Ro-31-8220,
has been shown to induce the activation of the MAP kinase, JNK
[19], and that PMA has been shown to promote the phosphorylation
and activation of the JNK substrate, the transcription factor c-Jun
[20], we decided to test whether c-Jun activation is effected by
PKC inhibitors. HUVECs were therefore stimulated for 30 min with
either F/R or PMA, or for various times with either 5 μM Ro-31-
7459 or 25 μM GÖ-6983. Cell extracts were then prepared and the
phosphorylation status of c-Jun was assessed by immunoblotting
with antibodies that recognise one of the JNK-dependent, activating
phosphorylations of c-Jun, at Ser 63 (Fig. 3A). Both F/R and PMA
were found to promote a robust phosphorylation of C-JUN on Ser
63 following 30 min stimulation, which was mirrored by a small up-
ward shift in electrophoretic mobility of the protein as detected by a
total c-Jun protein antibody (Fig. 3A). Surprisingly, however, incu-
bation of cells with Ro-31-7459 alone, but not GÖ-6983, also led to
phosphorylation of Ser 63 by 60 min, which increased further by
120 min coincident with a dramatic decrease in electrophoretic mo-
bility as detected by the total c-Jun antibody (Fig. 3A). This indicates
that Ro-31-7459 triggers multiple phosphorylations of c-Jun in
HUVECs and that these may be non-speciﬁc effects since they are
not observed when cells are stimulated with GÖ-6983.
To test this further, and to check for the PKC-dependency of
the effects of Ro-31-7459, HUVECs were stimulated for 60 min
with 5 μM Ro-31-7459, in the presence or absence of Gö 6983
and GF-109203X and then immunoblotted for antibodies to total
c-Jun or c-Jun phosphorylated on Ser 63 (Fig. 3B). Moreover,
since Ser 63 in c-Jun is a known phospho-acceptor site for MAP
kinases [21], cells were also treated with Ro-31-7459 in the pres-
ence or absence of a JNK inhibitor (SP600125) or an ERK inhibitor
(U0126). The relative activities of ERK and JNK were monitored by
immunoblotting with phospho-speciﬁc antibodies that recognised
the active forms of the enzymes. Stimulation with Ro-31-7459,but not Gö 6983 and GF-109203X, was found to promote a robust
phosphorylation of JNK and c-Jun, whereas all three inhibitors pro-
moted phosphorylation of ERK (Fig. 3B). The phosphorylation of Ser
63 of C-JUN in response to Ro-31-7459 was effectively inhibited by
the JNK inhibitor, but not the ERK inhibitor (Fig. 3B), suggesting
that JNK activation by Ro-31-7459, and not ERK activation, is the
responsible cause. Ro-31-7459-promoted Ser 63 phosphorylation
was not affected by the PKC inhibitors Gö 6983 and GF-109203X,
however, probably because they were unable to inhibit JNK activa-
tion in this experiment (Fig. 3B). However, long term down-
regulation of PKC isoforms, following chronic phorbol ester treat-
ment of cells [19], did effectively block both JNK activation and
phosphorylation of c-Jun on Ser-63 following stimulation with Ro-
31-7459 (Fig. 3C), suggesting that at least some of the actions of
Ro-31-7459 are dependent on PKC. Moreover, although both Gö
6983 and GF-109203X failed to inhibit Ser-63 phosphorylation
they both caused an increase in the electrophoretic mobility of
total C-JUN protein, indicating that they both inhibit a Ro-31-
7459-stimulated, PKC-dependent phosphorylation of c-Jun on a
site distinct from Ser-63. These results demonstrate that Ro-31-7459
displays cellular activities distinct from Gö 6983 and GF-109203X
in HUVECs that include the PKC-dependent and JNK-dependent
phosphorylation of c-Jun on Ser-63 and the PKC-dependent and
JNK-independent, phosphorylation of an additional site in c-Jun.
This site is highly likely to be one or more of three phosphor-
acceptor sites within the DNA-binding domain of c-Jun that have
been shown previously to be negatively regulated by PKC [22].
Moreover, although Ro-31-7459, Gö 6983 and GF-109203X all pro-
mote a strong activation of ERK in HUVECs, this does not appear to
affect the phosphorylation status of c-Jun in these cells, which is in
agreement with previous studies indicating that c-Jun in not a bone
ﬁde ERK substrate [23].
3.3. Cyclic AMP activates JNK to induce SOCS-3
Given that Ro-31-7459 is an effective inhibitor of cyclic AMP-
promoted SOCS-3 gene expression (Fig. 1) and a potent activator
of JNK MAP kinase signalling to c-Jun (Fig. 3), we next investigat-
ed the role of JNK in mediating cyclic AMP-induced SOCS-3 induc-
tion. HUVECs were therefore stimulated for various times with F/R
in the presence or absence of the broad speciﬁcity JNK inhibitor,
SP600125 (Fig. 4A). Immunoblotting cell extracts with phospho-
and activation-speciﬁc antibodies to JNK demonstrated that F/R
promoted a sustained activation of JNK between 60 and
300 min, which was completely ablated by incubation with
25 μM SP600125 (Fig. 4A). Moreover, immunoblotting HUVEC ex-
tracts from cells stimulated for 5 h with F/R, in the presence or
absence of chemical inhibitors of JNK (SP600125), ERK (U0126)
and p38 (SB202190) MAP kinases demonstrated that each MAP
kinase inhibitor reduced the ability of F/R to induce SOCS-3 ex-
pression over a range of concentrations (1–25 μM; Fig. 4B). To
investigate a role for c-Jun in cyclic AMP- and MAP kinase-
dependent SOCS-3 induction we next immunoblotted cell extracts
from cells treated with the same concentration range of MAP ki-
nase inhibitors with anti-phospho-Ser-63 c-Jun antibodies. Results
revealed that of the three MAP kinase inhibitors tested, only the
JNK inhibitor, SP00125, was able to inhibit F/R-induced c-Jun
phosphorylation, with a minimal effective concentration of
10 μM (Fig. 4C).
Together with the data presented in Fig. 3, these results sug-
gest that JNK activation, in addition to the activation of ERK and
p38 MAP kinases, may be an important component of the sig-
nalling mechanisms linking cyclic AMP elevation to the induc-
tion of SOCS-3 gene expression in HUVECs. However, JNK
activation by cyclic AMP, but not ERK or p38 activation, appears
to be coupled to the phosphorylation of c-Jun within its
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for SOCS-3 gene induction by cyclic AMP. Moreover, Ro-31-
7459 activates JNK and stimulates Ser-63 phosphorylation of c-Fig. 2. Elevation of intracellular cyclic AMP in HUVECs does not promote mobilisation of intra
in Hepes–Ca2+ buffer and then stimulated with either F/R or 10 μM ionomycin in the presen
sured at 340 nm and 380 nm for 5 min prior to the addition of reagents and then continued
dicated times with either F/R or PMA. Cell extracts were then prepared and immunob
phosporylated by PKC.Jun (Fig. 3), yet inhibits SOCS-3 induction (Fig. 1). The fact
that cyclic AMP also activates JNK, and yet promotes SOCS-3 in-
duction suggests that the inhibitory effects of Ro-31-7459 arecellular calcium or activation of protein kinase C. A). HUVECs were loaded with FURA-2
ce (upper panel) or absence (lower panel) of 10 μM BAPTA-AM. Fluorescence was mea-
for a further 20 min after addition of reagents. B). HUVECs were stimulated for the in-
lotted with antibodies that speciﬁcally detects multiple protein substrates that are
Time (minutes):
F/R
10 30 60 180 3000
F/R + SP600125 (25µM)
10 30 60 180 3000
Antibody
A
B
pJNK (Thr183/Tyr185)
Total JNK
F/R - + + + + + - + + + + +
0 0 25 10 1 0.1 0 0 25 10 1 0.1
- + + + + + - + + + + +
0 0 25 10 1 0.1 0 0 25 10 1 0.1
SB202190 (µM)SP600125 (µM)
F/R
U0126 (µM)SP600125 (µM)
SOCS-3
SOCS-3
F/R
U0126 (µM)SP600125 (µM)
C
pC-JUN (Ser 63) pC-JUN
Total C-JUN
SB202190 (µM)SP600125 (µM)
pC-JUN (Ser 63) 
Total C-JUN
pC-JUN
- + + + + + - + + + + +
0 0 25 10 1 0.1 0 0 25 10 1 0.1
F/R - + + + + + - + + + + +
0 0 25 10 1 0.1 0 0 25 10 1 0.1
Fig. 4. SOCS-3 induction following cyclic AMP elevation is dependent on activation of JNK MAP kinase in HUVECs. A). HUVECs were pre-treated with the JNK inhibitor, 25 μM
SP600125, and then stimulated with F/R for the indicated times. Cell extracts were the prepared and immunoblotted with antibodies to total JNK protein and anti-Thr183/
Tyr185 phospho-JNK antibodies as indicated. B). HUVECs were pre-incubated in the presence or absence of the indicated concentrations of the JNK inhibitor, SP600125, the ERK
inhibitor, U0126, or the p38 MAP kinase inhibitor, SB202190 and then stimulated for a further 3 h in the presence or absence of F/R. Cell extracts were then prepared and immu-
noblotted with anti-SOCS-3 and anti-β-tubulin antibodies. C). HUVECs were pre-incubated in the presence or absence of the indicated concentrations of SP600125, U0126 or
SB202190 and then stimulated for a further 3 h in the presence or absence of F/R. Cell extracts were then prepared and immunoblotted with anti-Ser63 phospho-c-Jun and
total-c-Jun antibodies.
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probably through PKC-dependent, phosphorylation of the c-Jun
DNA-binding domain [22].3.4. SOCS-3 gene induction requires AP-1 transcription factors
The induction of the SOCS-3 gene in response to elevations in
intracellular cyclic AMP in HUVECs is dependent on PKC and JNK
activation, both of which lead to the phosphorylation of c-Jun
(Figs. 1, 3 and 4). We therefore investigated whether c-Jun
is required for the transcriptional activation of the SOCS-3 gene.
C-Jun, in combination with c-Fos, is known to form part of the
AP-1 transcription factor complex, of which one has been identi-
ﬁed within the sequence of the murine SOCS-3 promoter region
[24] and this sequence is conserved in the human SOCS-3 pro-
moter (Fig. 5A). To test its importance of this site we generated
a deletion series of ﬁve human promoter constructs, together
with one promoter containing a mutation in the putative AP-1
transcription factor binding site, and cloned them into the promo-
terless ﬁreﬂy luciferase expression vector, pGL3-basic (Fig. 5A).
COS-1 cells were then co-transfected with the promoter con-
structs together with a Renilla luciferase vector and then stimulat-
ed for 16 h in the presence or absence 10 μM PMA, a knownactivator of AP-1 dependent transcription [20]. Cell lysates were
then prepared and luciferase activities measured (Fig. 5A). The ac-
tivity of ﬁreﬂy luciferase was compared to the activity of Renilla
luciferase, which was used as a control for transfection efﬁciency.
The truncated promoter constructs hSOCS3-1.7 kbp, hSOCS3-
1.1 kbp and hSOCS3-1.1-T1 all contain the putative AP-1 site and
show signiﬁcant increases in promoter activity in response to 10 μM
PMA stimulation (Fig. 5A). The truncated promoter constructs,
hSOCS-1.1-T2 and hSOCS3-1.1-T3 lack the putative AP-1 site and
show a considerable reduction in PMA stimulated promoter activity
(Fig. 5A). Moreover, a signiﬁcant reduction in both basal and stimu-
lated transcriptional activity was noted for the hSOCS-1.1-T1-AP-1
promoter construct, which contains a mutation in AP-1 site and is un-
able to bind c-Jun [24], compared to the hSOCS3-1.1-T1 promoter
(Fig. 5A). Together with previous work on the murine promoter
[24], the work presented here strongly suggests that the putative
AP-1 site within the human SOCS-3 promoter is important for PMA
regulated SOCS-3 transcription.
To conﬁrm that AP-1-depedent SOCS-3 transcriptional activation
is dependent on JNK activation, COS1 cells were transfected with
the hSOCS3-1.1-T1 minimal promoter construct and stimulated with
10 μM PMA for 16 h, in the presence or absence of inhibitors of JNK
(SP600125 and JNK inhibitor III), ERK (U0126) and p38 (SB202190)
MAP kinases (Fig. 5B). Results demonstrated that all of the MAP
1697J. Wiejak et al. / Cellular Signalling 24 (2012) 1690–1699kinase inhibitors caused a signiﬁcant reduction in the basal levels of
SOCS-3 promoter activity (Fig. 5B; upper panel), however only the
inhibitors of JNK and ERK MAP kinases caused a signiﬁcant reduc-
tion in PMA-stimulated SOCS-3 promoter activity (Fig. 5B; lower
panel). To conﬁrm that JNK and ERK MAP kinases can directly reg-
ulate the activity of AP-1 transcriptional activity, COS1 cells were
transfected with a luciferase reporter construct containing multiple
AP-1 sites and then stimulated with 10 μM PMA for 16 h, in the0 2 4
Re
-1160
-1100
-1060
-1032
-1700
AP1
hSOCS3-1.1k
hSOCS3-1.1-T
hSOCS3-1.1-T2 hS
-980
-1060
-1000
-1040
-1100-1120
-1160-1180
A
-1100
X
hSOCS3-1.7kbp
hSOCS3-1.1kbp
hSOCS3-1.1-T1
T1-delta AP1
hSOCS3-1.1-T2
hSOCS3-1.1-T3
pGL3-BASIC
Fig. 5. Activation of the human SOCS-3 promoter is dependent on AP-1 transcription factors.
ence of a conserved, putative AP-1 transcription factor binding site (upper panel). Truncatio
panel. COS-1 cells were co-transfected with a Renilla luciferase vector and the ﬁreﬂy luci
1.1-T1-AP-1, hSOCS3-1.1-T2 or hSOCS3-1.1-T3. Cells were then stimulated for 16 h in the pr
measured. Results were normalised to the activity of Renilla luciferase in cell extracts and r
tween the promoter truncates (including mutated promoter hSOCS3-1.1-T1-AP-1) relative t
between promoter constructs hSOCS3-1.1-T1 and hSOCS1-1.1-T1-AP-1, ###pb0.001. B). CO
T1 and Renilla luciferase. Cells were treated with 10 μM of the JNK inhibitors, SP202109 and
inhibitor, SB202190, and then stimulated, for 16 h, in the presence or absence of 10 μM PMA.
Relative Light Units (RLUs) in the upper panel and signiﬁcant reductions in the luciferase act
as are signiﬁcant decreases in basal activity, # (pb0.05), ## (pb0.01 and ### (pb0.001).
treated cells with signiﬁcant decreases in PMA-promoted luciferase activity following inhib
1 ﬁreﬂy luciferase reporter construct and Renilla luciferase. Cells were then treated with 1
the presence or absence of 10 μM PMA. Cells were then harvested and luciferase activitie
and signiﬁcant reductions in the luciferase activity of PMA stimulated cells relative to dilue
## (pb0.01 and ### (pb0.001). Results are also expressed as fold change in RLUs relative
luciferase activity following inhibitor treatment indicated, ***pb0.001.presence or absence of JNK (SP600125), ERK (U0126) and p38
(SB202190) MAP kinase inhibitors (Fig. 5C). We found that the in-
duction of AP-1 transcriptional activity was absolutely dependent
on JNK activation, since the JNK inhibitor, SP600125, completely ab-
lated AP-1 supported transcription (Fig. 5C). Moreover, inhibitors of
ERK and p38 MAP kinases had little effect on PMA-induced tran-
scriptional activity (Fig. 5C; lower panel), but rather signiﬁcantly re-
duced the basal transcriptional activity of the AP-1 reporter6 8 10 12 14 16
lative Light Units
PMA
Diluent
+946
+1
TATA
AP1 -99-105
bp
1
OCS3-1.1-T3
-1020
-1080
-1140
***
###
A). Comparison of the human and murine SOCS-3 promoter regions indicates the pres-
ns introduced into the human SOCS-3 promoter are indicated by arrows in the upper
ferase reporter constructs hSOCS3-1.7 kbp, hSOCS3-1.1 kbp, hSOCS3-1.1-T1, hSOCS3-
esence or absence of 10 μM PMA. Cells were then harvested and the luciferase activities
esults expressed as Relative Light Units. Signiﬁcant decreases in luciferase activity be-
o the promoter region hSOCS3-1.7 kbp are indicated, ***pb0.001, as are the differences
S-1 cells were co-transfected with the ﬁreﬂy luciferase reporter constructs hSOCS3-1.1-
JNK inhibitor IIII, 10 μM of the ERK inhibitor, U0126, or 10 μM of the p38 MAP kinase
Cells were then harvested and luciferase activities determined. Results are expressed as
ivity of PMA stimulated cells relative to diluent-treated cells are indicated, ***pb0.001,
Results are also expressed in the lower panel as fold change in RLUs relative to diluent
itor treatment indicated, ***pb0.001. C). COS-1 cells were co-transfected with an AP-
0 μM SP202109, 10 μM U0126, or 10 μM SB202190, and then stimulated, for 16 h, in
s determined. Results are expressed as Relative Light Units (RLUs) in the upper panel
nt-treated cells are indicated, ***pb0.001, as are signiﬁcant decreases in basal activity,
to diluent treated cells in the lower panel, with signiﬁcant decreases in PMA-promoted
hSOCS3-1.1-T1
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Diluent SP600125 JNK Inhibitor III SB202190 U0126
R
el
at
iv
e 
Li
gh
t U
ni
ts
Diluent
PMA
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
Diluent SP600125 JNK Inhibitor III SB202190 U0126
Fo
ld
 C
ha
ng
e 
in
 R
el
at
iv
e 
Li
gh
t U
ni
ts
Diluent
PMA
hSOCS3-1.1-T1
# ##
###
###
***
***
***
***
***
***
***
B
0
2
4
6
8
10
12
14
16
18
20
C
Diluent SP600125 SB202190 U0126
R
el
at
iv
e 
Li
gh
t U
ni
ts
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Diluent SP600125 SB202190 U0126
Fo
ld
 C
ha
ng
e 
in
 R
el
at
iv
e 
Li
gh
t U
ni
ts
Diluent
PMA
Diluent
PMA
***
***
***
***
##
##
AP-1
AP-1
Fig. 5 (continued).
1698 J. Wiejak et al. / Cellular Signalling 24 (2012) 1690–1699construct (Fig. 5C; upper panel). Together these results suggest that
although transcriptional induction of the human SOCS-3 promoter
displays a requirement for JNK and AP-1 dependent transcription,
this is not absolute and full transcriptional activity probably also re-
quires regulatory input from the ERK MAP kinase pathway, which is
probably regulating the transcription factor C/EBPβ, which we have
shown to be essential for ERK-dependent SOCS-3 induction in
HUVECs and COS1 cells [10,12]. The p38 MAP kinase pathway ap-
pears to be required for maintaining basal activity of the human
SOCS-3 promoter (Fig. 5B), perhaps through supporting basal activ-
ity of AP-1 transcription factors (Fig. 5C); however the mechanisms
underlying this effect remain to be determined.
To determine the effect of the PKC inhibitors on RO-317549
(5 μM), Gö-6983 (25 μM), GF-109203x (25 μM) on AP-1-dependent
induction of the SOCS-3 gene, COS1 cells transfected with the
hSOCS3-1.1-T1 were treated with the PKC inhibitors in the presence
or absence of 0.1 μM PMA and luciferase activities determined after
16 h (Fig. 6A). All three inhibitors signiﬁcantly reduced the PMA stim-
ulated activity of the minimal SOCS-3 promoter (Fig. 6A). To test this
further we decided to check whether RO-317549 (5 μM), Gö-6983
(25 μM) or GF-109203x (25 μM) modiﬁed the DNA-binding activity
of the c-Jun transcription factor itself. HUVECs were therefore stimu-
lated with 0.1 μM PMA, in the presence or absence of RO-317549
(5 μM), Gö-6983 (25 μM) or GF-109203x (25 μM), nuclear extracts
were prepared and the DNA-binding activity of C-JUN in cell extracts
was assessed by an ELISA-based activation assay which measure c-Junbinding to immobilised AP-1 DNA consensus sites (Fig. 6B). All three
PKC inhibitors were found to signiﬁcantly inhibit PMA-induced c-Jun
DNA binding ability indicating that this may underlie the part of the
mechanisms by which PKC inhibitors such as RO-317549 effectively
block SOCS-3 gene induction. Together with previous results this
demonstrates that SOCS-3 gene induction by cyclic AMP or PMA relies
on JNK-dependent activation of AP-1 transcription factors and that
the PKC inhibitor, RO-317549, promotes the PKC-dependent phos-
phorylation of the AP-1 transcription factor, c-Jun, which may con-
tribute to its ability to effectively block SOCS-3 gene induction in
HUVEC (Fig. 1) and COS1 cells [10].4. Conclusions
The bisindolemaleimide PKC inhibitor Ro-317549 triggers hyper-
phosphorylation of c-Jun in HUVECs in a JNK and PKC-dependent
manner, whereas structurally related GF-109203X andGö 6983 have lit-
tle effect. Despite this Ro-317549, GF-109203X and Gö 6983 all inhibit
PKC-dependent c-Jun activation. Using these inhibitors we demon-
strate that they all inhibit JNK-dependent c-Jun activation and c-Jun-
dependent induction of the SOCS-3 gene in response to elevations in
intracellular cyclic AMP. This demonstrates that, despite many off-
target effects, bisindolemaleimide PKC inhibitors reveal a central role
for the c-Jun transcription factor in controlling the induction of the
human SOCS-3 gene by cyclic AMP and PKC-dependent pathways.
Fig. 6. PKC-inhibitors block activation of the humanSOCS-3 promoter and activation of c-Jun
transcription factor. A). COS-1 cells were co transfected with the ﬁreﬂy luciferase reporter
construct hSOCS-1.1-T1 and Renilla luciferase. Cells were then pre-treated for 30 min with
5 μM Ro-317549, 25 μM Gö-6983, or 25 μM GF-109203X and then stimulated for 16 h, in
the presence or absence of 0.1 μM PMA. Cells were then harvested and the luciferase activi-
ties determined. Results expressed in Relative Light Units (RLUs) and signiﬁcant increases in
luciferase activity in PMA stimulated cells relative to diluents cells are indicated, ***pb0.001.
In addition, signiﬁcant decreases in luciferase activity in PMA-stimulated cells in the pres-
ence of Ro-317549, Gö-6983 andGF-109203X, relative to the diluent cells, are also indicated,
###pb0.001. B). HUVECs were pre-treated for 30 min with 5 μM Ro-317549, 25 μM
Gö-6983, or 25 μM GF-109203X and then stimulated for 3 h, in the presence or absence of
0.1 μM PMA. Nuclear extracts were then prepared, normalised for protein concentration.
Equal amounts of nuclear extract were then incubated with immoblised AP-1 DNA-
binding elements and the relative amounts of c-Jun binding were determined by ELISA
using a c-Jun-speciﬁc antibody. Results are expressed as relative absorbance units (OD
495 nm) and signiﬁcant decreases in PMA-induced DNA-binding in the presence of PKC
inhibitors are indicated, *pb0.05 and **pb0.01. The signiﬁcant increase in C-JUN activation
following PMA treatment is also indicated, ##pb0.01.
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